TGTX Price Earnings Ratio from 2010 to 2024
| TGTX Stock | USD 17.42 0.30 1.69% |
Price Earnings Ratio | First Reported 2010-12-31 | Previous Quarter 191.33469957 | Current Value 200.9 | Quarterly Volatility 71.33201855 |
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TGTX main balance sheet or income statement drivers, such as Depreciation And Amortization of 433.5 K, Interest Expense of 13.2 M or Total Revenue of 245.3 M, as well as many exotic indicators such as Price To Sales Ratio of 9.86, Dividend Yield of 4.0E-4 or PTB Ratio of 15.86. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
TGTX | Price Earnings Ratio |
Latest TG Therapeutics' Price Earnings Ratio Growth Pattern
Below is the plot of the Price Earnings Ratio of TG Therapeutics over the last few years. It is TG Therapeutics' Price Earnings Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Price Earnings Ratio | 10 Years Trend |
|
Price Earnings Ratio |
| Timeline |
TGTX Price Earnings Ratio Regression Statistics
| Arithmetic Mean | 20.90 | |
| Coefficient Of Variation | 341.31 | |
| Mean Deviation | 46.72 | |
| Median | (4.30) | |
| Standard Deviation | 71.33 | |
| Sample Variance | 5,088 | |
| Range | 222 | |
| R-Value | 0.56 | |
| Mean Square Error | 3,751 | |
| R-Squared | 0.32 | |
| Significance | 0.03 | |
| Slope | 8.96 | |
| Total Sum of Squares | 71,236 |
TGTX Price Earnings Ratio History
About TG Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include TG Therapeutics income statement, its balance sheet, and the statement of cash flows. TG Therapeutics investors use historical funamental indicators, such as TG Therapeutics's Price Earnings Ratio, to determine how well the company is positioned to perform in the future. Although TG Therapeutics investors may use each financial statement separately, they are all related. The changes in TG Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on TG Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on TG Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price Earnings Ratio | 191.33 | 200.90 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out the analysis of TG Therapeutics Correlation against competitors. For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for TGTX Stock analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is TG Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TG Therapeutics. If investors know TGTX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TG Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.3 | Revenue Per Share 2.017 | Quarterly Revenue Growth 7.135 | Return On Assets 0.1059 | Return On Equity 0.4393 |
The market value of TG Therapeutics is measured differently than its book value, which is the value of TGTX that is recorded on the company's balance sheet. Investors also form their own opinion of TG Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is TG Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TG Therapeutics' market value can be influenced by many factors that don't directly affect TG Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TG Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if TG Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TG Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.